Citations

Mayo Clinic

Clear

792 citation(s) found for "LACY, A".

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Dasari, Surendra , Grogan, Martha , Lacy, Martha Q. , Kourelis, Taxiarchis , Attia, Itzhak Z., Lopez‐Jimenez, Francisco, Murphree, Dennis H. , Friedman, Paul A. , Kumar, Shaji , Muchtar, Eli , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Attia, Itzhak Z., López-Jiménez, Francisco , Dispenzieri, Angela

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7230-7232

10.1182/blood-2022-168119 Get It

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
Murray, David , Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L., Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Claveau, Jean‐Sébastien , Dispenzieri, Angela , Binder, Moritz , Buadi, Francis K. , Dingli, David , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2347-2348

10.1182/blood-2022-167430 Get It

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
Kumar, Shaji , LaPlant, Betsy, Asmus, Erik, Thompson, Melanie , Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson I. , Muchtar, Eli , Dingli, David , Thompson, Melanie Ann, Go, Ronald S. , Dispenzieri, Angela , Leung, Nelson , Binder, Moritz , Rajkumar, S. Vincent , Gertz, Morie A.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10142-10143

10.1182/blood-2022-169046 Get It

Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
Goel, Utkarsh , Charalampous, Charalampos , Kapoor, Prashant , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Binder, Moritz , Buadi, Francis K. , Dingli, David , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Rajkumar, S. Vincent

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9998-9999

10.1182/blood-2022-160368 Get It

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
Zanwar, Saurabh , Larsen, Jeremy T. , Chanan‐Khan, Asher , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Lacy, Martha Q. , Lin, Yi , Sher, Taimur , Warsame, Rahma , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Ho, Matthew , Buadi, Francis K. , Ailawadhi, Sikander , Bergsagel, P. Leif , Binder, Moritz , Dingli, David , Dispenzieri, Angela , Fonseca, Rafaël , Gertz, Morie A. , Gonsalves, Wilson I. , Go, Ronald S. , Leung, Nelson , Muchtar, Eli , Roy, Vivek , Rajkumar, S. Vincent

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10017-10019

10.1182/blood-2022-167181 Get It

Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma
Schmidt, Walker M. , Hayman, Suzanne R. , Kumar, Shaji , Lacy, Martha Q. , Kapoor, Prashant , Warsame, Rahma , Kourelis, Taxiarchis , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Cook, Joselle , Leung, Nelson , Muchtar, Eli , Binder, Moritz , Gonsalves, Wilson I. , Gertz, Morie A.

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7182-7184

10.1182/blood-2022-156078 Get It

Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma
Nandakumar, Bharat , Abdallah, Nadine , Kumar, Shaji , Dingli, David , Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Warsame, Rahma , Kourelis, Taxiarchis , Kyle, Robert A. , Klug, Jason, Korfiatis, Panagiotis , Baffour, Francis , Abdallah, Nadine H , Kumar, Shaji K , Hwa, Yi Lisa, Kourelis, Taxiarchis V, Dingli, David , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Muchtar, Eli , Go, Ronald S. , Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson I.

Cancer | November 22, 2022 | Volume: 129 | Issue: 3 | Pages: 385-392

10.1002/cncr.34545 | PMID 36413412 Get It

BackgroundSarcopenia increases with age and is associated with poor survival outcomes in patients with cancer. By using a deep learning–based segmentation approach, clinical computed tomography (CT) images of the abdomen of patients with newly diagnosed multiple myeloma (NDMM) were reviewed to determine whether the presence of sarcopenia had any prognostic value.MethodsSarcopenia was detected by accurate segmentation and measurement of the skeletal muscle components present at the level of the L3 vertebrae. These skeletal muscle measurements were further normalized by the height of the patient to obtain the skeletal muscle index for each patient to classify them as sarcopenic or not.ResultsThe study cohort consisted of 322 patients of which 67 (28%) were categorized as having high risk (HR) fluorescence in situ hybridization (FISH) cytogenetics. A total of 171 (53%) patients were sarcopenic based on their peri‐diagnosis standard‐dose CT scan. The median overall survival (OS) and 2‐year mortality rate for sarcopenic patients was 44 months and 40% compared to 90 months and 18% for those not sarcopenic, respectively (p < .0001 for both comparisons). In a multivariable model, the adverse prognostic impact of sarcopenia was independent of International Staging System stage, age, and HR FISH cytogenetics.ConclusionsSarcopenia identified by a machine learning–based convolutional neural network algorithm significantly affects OS in patients with NDMM. Future studies using this machine learning–based methodology of assessing sarcopenia in larger prospective clinical trials are required to validate these findings.